Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
https://www.lilly.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers—General
Employés à temps plein: 39 000
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. David A. Ricks | Chairman, CEO & Pres | 4,42M | S.O. | 1968 |
Ms. Anat Ashkenazi | Exec. VP & CFO | 2,13M | S.O. | 1973 |
Dr. Daniel M. Skovronsky M.D., Ph.D. | Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories | 2,72M | S.O. | 1974 |
Ms. Anat Hakim J.D. | Exec. VP, Gen. Counsel & Sec. | 1,98M | S.O. | 1969 |
Mr. Patrik Jonsson | EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology | 1,67M | S.O. | 1967 |
Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. | S.O. | S.O. | S.O. |
Mr. Diogo Rau | EVP & Chief Information and Digital Officer | S.O. | S.O. | S.O. |
Mr. Alonzo Weems | EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer | S.O. | S.O. | 1971 |
Ms. Leigh Ann Pusey | Exec. VP of Corp. Affairs & Communications | S.O. | S.O. | 1963 |
Mr. Eric Dozier | Exec. VP of HR & Diversity | S.O. | S.O. | 1967 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
L’ISS Governance QualityScore de Eli Lilly and Company en date du 1 juin 2023 est 5. Les scores principaux sont Audit : 3; Société : 5; Droits des actionnaires : 9; Compensation : 1.